2 unknown, 1 not yet recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Jing Li: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating the Efficacy of Hyperthermic Intraperitoneal Treatment to Enhance the Sensitivity of Immune Checkpoint Inhibitor in Patients With Advanced Ovarian Cancer： A Single-arm Study ICI-HIPET - HIPEC, Ovarian Serous Adenocarcinoma | Phase 2 | Not yet recruiting | Jing Li | 30 | 2025-08-01 | 2025-07-16 |
| Dynamic Monitoring of ctDNA Predicts Recurrence of Advanced Ovarian Cancer After Primary Treatments Ovarian Cancer Stage IV, Ovarian Cancer Stage III | Unknown | Jing Li | 50 | 2022-08-01 | 2023-09-06 | |
| Impact of HMGB1 on Diastolic Dysfunction in Hypertensive Patients Diastolic Dysfunction, Hypertension | Unknown | Jing Li | 100 | 2017-08-15 | 2017-06-06 |
Hypertension (1) · Inflammation (1) · Ovarian Neoplasms (1)
China (2)